The effect of three dimensional activity distribution on dose planning of radioimmunotherapy for patients with advanced intraperitoneal pseudomyxoma

Cancer

Volumn 80, Issue 12 SUPPL., 1997, Pages 2545-2552

  Laitinen, Joakim O ^a,b   Kairemo, Kalevi J A ^c   Jekunen, Antti P ^c   Korppi Tommola, Tapani ^c   Tenhunen, Mikko ^c  

^a Varian Dosetek Oy   (Finland)

^b AALTO UNIVERSITY   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Dosimetry; Pseudomyxoma peritonei; Radioimmunotherapy; Single photon emission computed tomography; Treatment planning

Indexed keywords

MONOCLONAL ANTIBODY B.72.3 I 131;

CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; COMPUTER PROGRAM; CONFERENCE PAPER; DOSE CALCULATION; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; PERITONEUM PSEUDOMYXOMA; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; SCINTILLATION CAMERA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT PLANNING;

EID: 0031443244     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(19971215)80:12+<2545::aid-cncr29>3.0.co;2-b     Document Type: Conference Paper

References (37)

1. Kairemo KJA. Radioimmunotherapy of solid cancers. A review. Acta Oncol 1996;35:343-55.
2. Strand S-E, Jönsson B-A, Ljungberg M, Tennvall J. Radioimmunotherapy dosimetry. A review. Acta Oncol 1993;32:807-17.
3. Fisher DR. Radiation dosimetry for radioimmunotherapy. An overview of current capabilities and limitations. Cancer 1994;73:905-11.
4. Sgouros G, Chiu S, Pentlow KS, Brewster LJ, Kalaigian H, Baldwin B, et al. Three-dimensional dosimetry for radioimmunotherapy treatment planning. J Nucl Med 1993;34:1595-601.
5. Sgouros G, Barest G, Thekkumthala J, Chui C, Mohan R, Bigler RE, et al. Treatment planning for internal radionuclide therapy: three-dimensional dosimetry for nonuniformly distributed radionuclides. J Nucl Med 1990;31:1884-91.
6. Giap HB, Macey DJ, Podoloff DA. Development of a SPECT-based three-dimensional treatment planning system for radioimmunotherapy. J Nucl Med 1995;36:1885-94.
7. Giap HB, Macey DJ, Bayouth JE, Boyer AL. Validation of a dose-point kernel convolution technique for internal dosimetry. Phys Med Biol 1995;40:365-81.
8. Erdi AK, Loew M, Yorke E, Erdi Y, Wessels B. Use of the fast Hartley transform for efficient 3D convolution in calculation of radiation dose. In: Proceedings of the 16th Annual IEEE-EMBS Conference. Piscataway:IEEE, 1994:639-40.
9. Hossain J, Malabarey T, al Mofleh I, Hawass NE, Ismail AH. Clinical and radiological features of pseudomyxoma peritonei. J R Soc Med 1989;82:600-2.
10. Wertheim I, Fleischhacker D, McLachlin CM, Rice LW, Berkowitz RS, Goff BA. Pseudomyxoma peritonei: a review of 23 cases. Obstet Gynecol 1994;84:17-21.
11. Smith JW, Kemeny N, Caldwell C, Banner P, Sigurdson E, Huvos A. Pseudomyxoma peritonei of appendiceal origin. The Memorial Sloan-Kettering Cancer Center experience. Cancer 1992;70:396-401.
12. el Sayed S. Pseudomyxoma peritonei treated by radiotherapy. Clin Oncol (R Coll Radiol) 1990;2:120-2.
13. Sugarbaker PH. Surgical treatment of peritoneal carcinomatosis: 1988 Du Pont lecture. Can J Surg 1989;32:164-70.
14. Kairemo KJA, Jekunen AP, Bondestam S, Korppi-Tommola ET, Savolainen S, Paavonen T. Detection of pseudomyxoma peritonei by radioimmunohistochemistry and radioimmunoscintigraphy. Cancer Biother Radiopharm 1996;11:325-34.
15. Odyssey VP operators guide. Volume 1. Chapter 6.1.10. Highland Heights: Picker Ohio Imaging Division, 1995.
16. Leichner PK. A unified approach to photon and beta particle dosimetry. J Nucl Med 1994;35:1721-9.
17. Berger MJ. Energy deposition in water by photons from point isotropic sources. MIRD Pamphlet No. 2. J Nucl Med 1968;1:17-25.
18. Berger MJ. Distribution of absorbed dose around point sources of electrons and beta particles in water and other media. MIRD Pamphlet no. 7. J Nucl Med 1971;12 (Suppl 5): 5-23.
19. ICRU 32. Methods of assessment of absorbed dose in clinical use of radionuclides. Washington DC: International Commission on Radiation Units and Measurements, 1979:28-32.
20. Furhang EE, Sgouros G, Chui C-S. Radionuclide photon dose kernels for internal emitter dosimetry. Med Phys 1996;23: 759-64.
21. Nelson WR, Hirayama H, Rogergs DWO. The EGS4 code system. SLAC Report No. 265. Stanford, CA: SLAC, 1985.
22. 2 fragments of monoclonal antibody in humans. Med Phys 1984;11:778-83.
23. Colcher D, Horan-Hand P, Nuti M, Schlom J. A spectrum of monoclonal antibodies reactive with human mammary tumor cells. Proc Natl Acad Sci USA 1981;78:3199-203.
24. Schlom J, Siler K, Colcher D, Carrasquillo JA, Reynolds JC, Sugarbaker PH, et al. Binding of radiolabeled MAb B72.3 administered intravenously and intraperitoneally in colorectal cancer patients. An overview. Acta Radiol Suppl 1990;374:123-8.
25. Roselli M, Hitchcock CL, Molinolo A, Milenic DE, Colcher D, Martin EW Jr., et al. Autoradiographic evaluation of monoclonal antibody B72.3 distribution in tumor and lymph nodes of adenocarcinoma patients. Anticancer Res 1995;15: 975-84.
26. Larson SM, Carrasquillo JA, Colcher DC, Yokoyama K, Reynolds JC, Bacharach SA, et al. Estimates of radiation absorbed dose for intraperitoneally administered iodine-131 radiolabeled B72.3 monoclonal antibody in patients with peritoneal carcinomatoses. J Nucl Med 1991;32:1661-7.
27. Erdi AK, Erdi YE, Yorke ED, Wessels BW. Treatment planning for radio-immunotherapy. Phys Med Biol 1996;41:2009-26.
28. Leichner PK, Koral KF, Jaszczak RJ, Green AJ, Chen GTY, Roeske JC. An overview of imaging techniques and physical aspects of treatment planning in radioimmunotherapy. Med Phys 1993;20:569-77.
29. Macey DJ, Grant EJ, Bayouth JE, Giap HB, Danna SJ, Sirisrior R, et al. Improved conjugate view quantitation of I-131 by subtraction scatter and septal penetration events with a triple energy window method. Med Phys 1995;22:1637-43.
30. Ljungberg M, King MA, Hademenos GJ, Strand SE. Comparison of four scatter correction methods using Monte Carlo simulated source distributions. J Nucl Med 1994;35:143-151.
31. Koral KF, Zasadny KR, Kessler ML, Luo J-Q, Buchbinder SF, Kaminski MS, et al. CT-SPECT fusion plus conjugate views for determining dosimetry in iodine-131-monoclonal antibody therapy of lymphoma patients. J Nucl Med 1994;35: 1714-20.
32. Pohjonen H, Nikkinen P, Sipilä O, Launes J, Salli E, Salonen O, et al. Registration and display of brain SPECT and MRI using external markers. Neuroradiology 1996;38:108-14.
33. Koral KF, Lin S, Fessler JA, Kaminski MS, Wahl RL, Meyer CR, et al. Potentially-marker-free registration of CT with I-131 anti-B1 monoclonal-antibody intratherapy SPECT [abstract]. Tumor Targeting 1996;2:174.
34. van Herk M, Kooy HM. Automatic three-dimensional correlation of CT-CT, CT-MRI, and CT-SPECT using chamfer matching. Med Phys 1994;21:1163-78.
35. Furhang EE, Chui C-S, Sgouros G. A Monte Carlo approach to patient-specific dosimetry. Med Phys 1996;23:1523-9.
36. Tagesson M, Ljungberg M, Strand SE. A Monte Carlo program converting activity distributions to absorbed dose distributions in a radionuclide treatment planning system. Acta Oncol 1996;35:367-72.
37. Watson EE, Stabin MG, Siegel JA. MIRD formulation. Med Phys 1993;20:511-4.